Dandelion Science is a US-Swiss neuromodulation company developing the first generative AI platform for synthesizing precision sensory stimulation therapies targeting neurodegenerative and neuropsychiatric disorders. Headquartered in Hoboken, New Jersey, with a subsidiary in Lausanne, Switzerland, the company operates at the intersection of generative AI, computational neuroscience, and non-invasive brain stimulation.

The platform uses generative artificial intelligence to model brain network dynamics and synthesize, on demand, sensory stimulation protocols designed to modulate specific neural circuits. The computational approach emulates the way the brain itself processes information, aiming to produce therapies that precisely match the complex dysfunctions characteristic of conditions such as vision loss, Alzheimer's disease, and neuropsychiatric disorders. The company holds extensive intellectual property and has received funding from the NIH and the Swiss Innovation Agency.

Dandelion's initial focus includes precision therapies for vision and brain disorders, with a four-year research partnership with the Wyss Center for Bio and Neuroengineering providing access to clinical partners, neuroscience expertise, and integration into a broader neurotechnology ecosystem. The company positions itself in an emerging therapeutic category it terms Generative Neuromodulation, targeting both clinical populations and eventual broader neurological applications.